AWARD NUMBER: DAMD17-00-1-0719

TITLE: Hepatitis C Virus Infection: Mechanisms of Disease Progression

PRINCIPAL INVESTIGATOR: Maria H. Sjogren, Ph.D.
Brooke Huntley

CONTRACTING ORGANIZATION: T.R.U.E. Research Foundation
San Antonio, Texas 78217-1239

REPORT DATE: October 2007

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
An estimated 4.1 million individuals in the USA are chronically infected with the hepatitis C virus. Annually, 8,000 to 10,000 of these subjects will die of liver-related complications and approximately 1,000 will require liver transplantation. The United States military has rates of HCV infection similar to the general US population (1.6%). However, it is a younger population and its natural history of HCV infection has not been studied. Therefore, the clinical outcome of HCV-infected military subjects and risk factors contributing to disease progression are largely unknown. Such knowledge is essential for decisions regarding optimal management and prevention of the disease. This study focuses on active duty military subjects infected with HCV, who will be enrolled and observed prospectively over four years (48 months). Liver biopsies are to be performed at initiation if needed and at completion of study to observe for disease progression. Lab evaluation of virologic and biochemical indicators of the disease and detailed information about risk factors, and quality of life are collected by questionnaire every six months. Currently, 95 subjects have been enrolled, 29 have completed all observations, 12 are still under observation, 3 died (unrelated causes) and the rest stopped their participation in the trial early. We report conclusions on the data in terms of disease progression and potential contributing factors to disease progression specific to this population on the entire cohort, although data collection are incomplete.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>8</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>8</td>
</tr>
<tr>
<td>Conclusions</td>
<td>9</td>
</tr>
<tr>
<td>References</td>
<td>9</td>
</tr>
<tr>
<td>Appendices</td>
<td>9</td>
</tr>
</tbody>
</table>
INTRODUCTION

An estimated 4.1 million individuals in the USA are chronically infected with the Hepatitis C virus. Annually, 8,000 to 10,000 of these people will die of liver related complications and approximately 20,000 are waitlisted for liver transplantation with 20% actually receiving a new liver. Thus, HCV is a major public health problem. The US military population has rates of HCV infection similar to the general US population with an overall rate of 1.6%. However, it is a younger population and the natural history of HCV infection in the population has not been studied. Therefore, the clinical outcome of HCV infected military subjects is largely unknown. Specific factors in military life have not been studied to observe if they contribute to disease progression. Such knowledge is essential for decisions regarding optimal prevention and management of the disease.

Active duty service members with chronic HCV infection will be enrolled and observed prospectively over four years in this study. Our principal hypothesis is that in active duty members infected with HCV genotype-1, liver disease progresses more rapidly than in subjects infected with HCV non-genotype-1. The effect of other factors that might influence histologic progression of liver disease including age, race, rank, deployment, alcohol consumption, and HCV RNA level will be assessed. To test this hypothesis we have the following specific aims:

- To compare the rate of progression of liver disease based on a histologic severity scale in military subjects infected with genotype-1 to the rate of progression in those infected with non-genotype-1.
- To identify other predictors of progression of histologic liver disease in a military population.
- To determine risk factors for acquisition of genotype-1 compared to non-genotype-1 HCV.
- To describe the natural history of HCV infection in a group of a military population.

BODY

To date 29 subjects have completed the study. There are 12 active participants (participants currently being followed) ranging in status from month 6 to month 42. In addition, to the 41 active or finished participants, 3 are deceased (causes unrelated to HCV infection, one was due to AIDS, one brain tumor and another one due to orthotopic liver rejection), 3 withdrew consent and 43 have been last to follow-up, after attempts to contact them during the last 12 months. Of those who terminated early, reasons cited included too far to travel, felt the questions were not relevant, others cited no specific reason. Enrollment is closed.  Figure 1.

This is not an interventional study, no adverse events have been reported since the last APR.

Sample Demographics:

- 84% of the sample is male.
- The current ages of the subjects range from 20 to 60. The mean age is 44.
20% of the sample is African American. 62% are Caucasian, 11% are Latino, 6% are Asian, and 1% are of unknown ethnicity (see figure 2).

Figure 2.

Baseline Lab/Histology Data:
By and large the sample does not have indicators of advanced (decompensated) liver disease as evidenced by biochemical indicators. At baseline, the mean PT is 13.47, mean albumin is 4.23, and mean ALT is 102.54.
- 40.3% of the sample had ALT less than 72, which is the high limit for males at WRAMC laboratories.
- 73% of the sample is genotype-1, 21.4% is genotype-non-1, and 1.2% of the sample is unknown.
- 62% of the sample had viral loads >500,000 IU/mL. Of the total sample, 11.3% had viral loads >850,000 IU/mL.
- 21.6% of the sample had no or minimal fibrosis. 28.4% of the sample showed signs of periportal fibrosis and 28.4% of the sample had bridging fibrosis. 4.1% of the sample had cirrhosis.

Lifestyle Factors potentially contributing to disease acquisition or progression:
- 11% of the sample self reports having a drinking problem now or in the past.
- 11% has had a DUI.
- 26% of the sample have answered one of the CAGE questions affirmatively.
- 66% of the sample has a tobacco use history, but only 27% are current smokers.
- 19% had been incarcerated.
- 38% of the sample has had more than 10 sexual partners.
- 16% has had sexual intercourse with a prostitute.

Risk Factor Analysis (see figure 3):
- 21% of the sample has a prior history of blood transfusion.
- 47% has at least one body piercing.
- 48% of the sample is tattooed.
- 14% has had acupuncture.
- 6% has had needle sticks.
- 33% has been in combat.
• 6% of the sample has a past history of IV Drug Use.
• 67% report having had cutaneous exposure to somebody else’s blood.
• 64% shared nail trimming instruments.

Figure 3.

We were able to examine this preliminary data to see if any trends or patterns emerged, specifically with respect to our aim of determining if there were any specific risk factors for acquisition of genotype-1 compared to non-genotype-1 HCV (see tables 1 and 2). Although not significant, trends emerged suggesting, in general, genotype-1 infected individuals may be more likely to have lifestyle risk factors whereas, genotype non-1 may be more likely to have other risk factors.

Table 1.

<table>
<thead>
<tr>
<th>Lifestyle Risk Factors</th>
<th>Incarceration</th>
<th>IV Drug Use</th>
<th>Drinking Problem</th>
<th>DUI</th>
<th>Sex with &gt;10 Partners</th>
<th>Sex w/a Prostitute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype-1</td>
<td>14.8%</td>
<td>5.6%</td>
<td>9.3%</td>
<td>13.0%</td>
<td>37.0%</td>
<td>18.5%</td>
</tr>
<tr>
<td>Genotype Non-1</td>
<td>27.8%</td>
<td>5.6%</td>
<td>16.7%</td>
<td>5.6%</td>
<td>38.8%</td>
<td>5.6%</td>
</tr>
</tbody>
</table>

Table 2.

<table>
<thead>
<tr>
<th>Other Risk Factors</th>
<th>Transfusion</th>
<th>Acupuncture</th>
<th>Tattoo</th>
<th>Piercing</th>
<th>Exposure to Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype-1</td>
<td>20.4%</td>
<td>13.0%</td>
<td>48.1%</td>
<td>46.3%</td>
<td>66.7%</td>
</tr>
<tr>
<td>Genotype</td>
<td>22.2%</td>
<td>16.7%</td>
<td>50.0%</td>
<td>50.0%</td>
<td>66.7%</td>
</tr>
</tbody>
</table>
Looking at the relationship between genotype and demographics revealed that 61.0% of officers were genotype-1 while 80.1% of the enlisted subjects were genotype-1 (see figure 4). This difference was not significant.

*Figure 4.*

![Genotype Classification Across Rank](image)

**Quality of Life:**
- 19.4% of the sample feels that they have been limited by their HCV in the past two weeks in performing their daily work at least some of the time during the past two weeks.
- 18.1% of the sample feels that their HCV has limited their activities (walking, climbing, stairs, carrying groceries, playing sports) at least some of the time in the past two weeks.
- 43.1% of the sample has had difficulty sleeping at night at least some of the time during the last two weeks.
- 48.6% of the sample worried at least some of the time during the past two weeks that their symptoms will develop into major problems.
- 44.4% of the sample worried at least some of the time during the past two weeks that they might die earlier than expected because of their Hepatitis C.
- 30.6% of the sample experienced emotional stress or strain in their relationships at least some of the time during the past two weeks as a result of their hepatitis C.

These data are generated from the chronic liver disease questionnaire-HCV (CLDQ-HCV), which is asked at baseline and each patient visit. The above results express how subjects (n=95) felt at their most recent visit—regardless of treatment status. An additional Quality of Life questionnaire, the SF-36 of Hepatitis Quality of Life Questionnaire (HQLQ), is also administered at each visit. Upon completion of the study, HQLQ data will be scored by a professional scoring service, therefore, no analysis is available at the time of this report.

**Therapy Outcomes**
- Although the subjects enrolled in this study do not receive any anti viral therapy as a part of the study, a number of subjects have/are enrolled in other studies involving treatment and/or have received such treatment at the WRAMC Liver Clinic. The below statistics were calculated for the 95 patients that were enrolled for the study.
  - 62% of the sample has been exposed to an Interferon treatment while participating in this study.
  - Of those exposed to Interferon treatment, currently,
    - 66% are currently showing a viral response or have a sustained viral response to the treatment and currently have undetectable HCV viral loads.
    - 32.1% did not respond or relapsed after showing initial response to the treatment.
    - 1.9% has an unknown current status.
Analysis of alanine aminotransferase (ALT) and HCV viral load at baseline and at end of observation

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Mean baseline ALT</th>
<th>End of observation ALT</th>
<th>Baseline HCV RNA</th>
<th>End of observation HCV RNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed cohort</td>
<td>29</td>
<td>122</td>
<td>75</td>
<td>High Viral load 18</td>
<td>High Viral load 14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low viral load 5</td>
<td>Low viral load 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Negative 3</td>
<td>Negative 15</td>
</tr>
<tr>
<td>Active cohort</td>
<td>12</td>
<td>88</td>
<td>53.5</td>
<td>High Viral load 8</td>
<td>High Viral load 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low viral load 2</td>
<td>Low viral load 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Negative N/A 2</td>
<td>Negative 9</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>42</td>
<td>84</td>
<td>41</td>
<td>High Viral load 27</td>
<td>High Viral load 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low viral load 7</td>
<td>Low viral load 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Negative 8</td>
<td>Negative 12 (11 not available )</td>
</tr>
</tbody>
</table>

High viral load: ≥ 400,000 IU/mL
Low viral load: <400,000 IU/mL

Assessment of ALT and HCV RNA data: The average ALT decreased over time in most subjects, probably due to several of them receiving antiviral therapy. Similarly the number of negative HCV RNA increased, probably due to the same antiviral factor. Importantly only one patient progressed to liver transplantation and subsequently died due to rejection of the liver. All other patients appear to have compensated liver disease.

KEY RESEARCH ACCOMPLISHMENTS

Enrolled 95 subjects.

REPORTABLE OUTCOMES

Average % Changes in Labs after One Year:
- Subjects Receiving Treatment in First Year
  - ALT decreased 58%
  - Albumin decreased 2.52%
  - Platelets decreased 7.14%
  - Prothrombin Time increased 0.90%
- Subjects Receiving NO Treatment in First Year
  - ALT decreased 1.33%
  - Albumin decreased 0.53%
  - Platelets decreased 5.66%
  - Prothrombin Time decreased 4.66%

Change in Quality of Life during the First Year:
- Subjects Receiving Treatment in First Year
  - Depression increased 18%
  - Mood Swings decreased 13.7%
  - Irritability decreased 23.7%
Data suggests that laboratory values improve with treatment. In addition, untreated subjects are significantly more likely to report feeling depressed, having increased irritability, and having greater mood swings than those that are treated.

CONCLUSIONS

Inferences cannot be made about histological progression of hepatitis C in this population as there have only been twenty-nine (30%) subjects that have completed the study. Until there are more patients with complete study data including the second liver biopsy conclusions are unavailable. However, interesting trends are beginning to emerge with respect to genotype, military rank, risk factors, and the impact of treatment. As more data is obtained, analysis that looks at the other indicators of disease progression such as biochemical markers will also be able to be performed. Additionally, it is hoped that the morbidity and quality of life data will lend insight into an under-researched area of study in this disease process in the active duty military population.

REFERENCES

None at this time.

APPENDICES

Not applicable.